Intuitive Surgical Inc (ISRG) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$377.16

Open

$378.02

Day range

$377.16 – $387.29

Volume

2.1M

About Intuitive Surgical Inc

Latest ISRG news

• Intuitive Surgical (ISRG): Embracing AI Innovations in Robotic Surgery for Future Growth
  Yahoo Finance · Sep 7, 2026

  Intuitive Surgical (ISRG) is positioning itself for future growth by integrating artificial intelligence innovations into its robotic surgery systems. The company, known for its da Vinci surgical system, is not only focused on selling new robots but is also emphasizing the importance of parts and services for existing machines, which is a critical component of its business model. This strategy allows Intuitive Surgical to maintain a steady revenue stream while expanding its market presence in general surgery and other emerging specialties beyond its traditional urology stronghold. The integration of AI into robotic surgery could enhance surgical precision and efficiency, potentially leading to better patient outcomes and reduced recovery times. As the healthcare sector increasingly adopts advanced technologies, Intuitive Surgical's commitment to innovation may provide a competitive edge, particularly as it faces competition from newer entrants like SS Innovations. Market analysts are closely watching how these developments will impact Intuitive Surgical's financial performance and market share, especially in a landscape where the demand for minimally invasive procedures continues to rise. Investors may view the company's focus on AI as a positive indicator for long-term growth, despite the challenges posed by competition and market dynamics.

• Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?
  Yahoo Finance · Sep 5, 2026

  Intuitive Surgical (NASDAQ: ISRG), the leading manufacturer of robotic-assisted surgical systems, has seen its stock price decline over 30% since the beginning of 2026, raising questions among investors about the sustainability of its growth trajectory. While the company reported strong second-quarter results, exceeding both revenue and earnings expectations, concerns have emerged regarding a slowdown in domestic procedure growth, which has overshadowed its financial performance. The company's business model heavily relies on selling parts and services for its existing surgical robots rather than new unit sales. This shift in focus has led to a more stable, albeit slower, growth rate as the market matures. Investors are now weighing whether the current dip in stock price represents a buying opportunity or a signal of deeper issues within the company. Analysts suggest that while the long-term prospects for robotic surgery remain strong, the immediate outlook may be clouded by reduced demand for new installations and potential market saturation. As Intuitive Surgical navigates this transitional phase, its ability to maintain profitability and expand its service offerings will be critical. The stock's performance in the coming months will likely hinge on how effectively the company can address these growth concerns and adapt to changing market dynamics. Investors should remain vigilant, as the balance between innovation and market demand will play a pivotal role in determining the future value of Intuitive Surgical's shares.

• Why hire a warehouse worker for $30 per hour when a robot costs $10? JPMorgan expects booming humanoid demand.
  MarketWatch · Aug 25, 2026

  JPMorgan has released a report projecting a significant increase in demand for humanoid robots, highlighting a growing trend in automation that could reshape labor markets. The report underscores the economic rationale behind investing in humanoid robots, which can be deployed at a fraction of the cost of human labor—$10 per hour compared to $30 for warehouse workers. This cost differential is expected to drive businesses to adopt robotic solutions more aggressively, particularly in sectors where labor shortages and rising wage pressures are prevalent. As companies increasingly turn to automation to enhance efficiency and reduce operational costs, the implications for the labor market could be profound. The shift towards humanoid robots may lead to job displacement in low-skill sectors, while simultaneously creating demand for skilled workers who can design, maintain, and program these advanced machines. Furthermore, the anticipated growth in the humanoid robotics market could spur investment in technology firms specializing in robotics, potentially leading to a surge in stock prices within this sector. Overall, the JPMorgan report suggests that as businesses weigh the long-term benefits of automation against immediate labor costs, the trend towards humanoid robots may accelerate, fundamentally altering the landscape of workforce dynamics and economic productivity in the coming years.

• Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
  Yahoo Finance · Aug 23, 2026

  Investors in the healthcare sector are currently weighing the merits of two prominent companies: Danaher Corporation and Intuitive Surgical. Danaher, a diversified conglomerate known for its life sciences and diagnostics segments, is emerging from a period of slower growth, primarily due to pandemic-related disruptions. As the global healthcare landscape stabilizes, Danaher is poised to benefit from increased demand for its products and services, particularly in diagnostics and bioprocessing. Analysts suggest that the company's robust portfolio and operational efficiencies could lead to a strong recovery trajectory, making it an attractive option for conservative investors seeking stability. In contrast, Intuitive Surgical, the pioneer of robotic-assisted surgery with its da Vinci Surgical System, is focused on innovation and expanding its market share. The company has consistently invested in research and development to enhance its surgical systems and expand their applications across various medical fields. As healthcare providers increasingly adopt robotic-assisted procedures, Intuitive Surgical is well-positioned for long-term growth. However, the company faces challenges, including rising competition and regulatory scrutiny, which could impact its market performance. The decision between investing in Danaher or Intuitive Surgical ultimately hinges on an investor's risk tolerance and growth expectations. Danaher offers a recovery play with potential for steady returns as it rebounds from recent setbacks, while Intuitive Surgical presents a more aggressive growth opportunity driven by innovation. As both companies navigate the evolving healthcare landscape, their respective strategies will be critical in determining their long-term success and appeal to investors.

• Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?
  Yahoo Finance · Aug 23, 2026

  Thermo Fisher Scientific and Intuitive Surgical, both leaders in the healthcare sector, are currently under scrutiny as investors evaluate their respective valuations amid strong quarterly performances. Thermo Fisher has positioned itself as a key player in the life sciences industry, with its growth increasingly tied to ongoing investments in research and development. Meanwhile, Intuitive Surgical, known for its robotic surgical systems, reported a significant surge in Q2 2026, showcasing its competitive advantages and a robust recurring revenue model. Despite their strong results, market reactions have diverged sharply. While Abbott Laboratories raised its annual profit outlook following a solid quarter, Intuitive Surgical's elevated valuation has led analysts to adopt a more cautious stance, rating it as a "Hold." Investors are now questioning the sustainability of Intuitive Surgical's growth trajectory, particularly in light of recent earnings that may not fully align with lofty expectations. This skepticism could impact the stock's performance in the near term, as market participants weigh the potential for future growth against its current price. As the healthcare sector continues to evolve, the contrasting market responses to Thermo Fisher and Intuitive Surgical highlight the complexities of valuing premium stocks. Investors must consider not only the companies' financial metrics but also the broader industry trends and the potential for innovation that could drive long-term growth. The outcome of this evaluation will be critical in determining which stock justifies its premium valuation in an increasingly competitive landscape.

• Orthopedic Spine Navigation System Market Outlook Signals Expansion To $27.84 Billion Through 2030
  Market Outlook · Aug 21, 2026

  The Orthopedic Spine Navigation System market is poised for significant growth, projected to expand from $19.91 billion in 2026 to $27.84 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.7%. This anticipated increase is driven by advancements in artificial intelligence (AI)-driven navigation technologies and their integration with robotic surgical platforms, which enhance precision and efficiency in spinal surgeries. As the healthcare sector increasingly adopts innovative technologies, the demand for orthopedic spine navigation systems is expected to rise. These systems leverage imaging and computer guidance to provide real-time insights into spinal anatomy, improving surgical outcomes through enhanced planning and navigation. The convergence of AI and robotics in this field not only streamlines surgical procedures but also reduces recovery times, making these systems appealing to both healthcare providers and patients. Market analysts suggest that the growth of the orthopedic spine navigation system market could have broader implications for the medical device industry, potentially attracting investments and fostering further technological innovations. As hospitals and surgical centers seek to improve patient care and operational efficiency, the adoption of these advanced navigation systems may become a standard practice, reshaping the landscape of orthopedic surgery.

Index membership

• S&P 500 · Health Care
• Nasdaq-100 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen